Bret Christensen - Insulet Ex Officer

GOV Stock  EUR 245.00  0.40  0.16%   

Insider

Bret Christensen is Ex Officer of Insulet
Age 52
Phone978 600 7000
Webhttps://www.insulet.com

Insulet Management Efficiency

The company has return on total asset (ROA) of 0.0183 % which means that it generated a profit of $0.0183 on every $100 spent on assets. This is way below average. Insulet's management efficiency ratios could be used to measure how well Insulet manages its routine affairs as well as how well it operates its assets and liabilities.
Insulet has accumulated 1.37 B in total debt with debt to equity ratio (D/E) of 272.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Insulet has a current ratio of 4.27, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Insulet until it has trouble settling it off, either with new capital or with free cash flow. So, Insulet's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Insulet sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Insulet to invest in growth at high rates of return. When we think about Insulet's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Jeffrey MirvissBoston Scientific
57
Jennifer OlsonWilkAlign Technology
45
Hubert AllenAbbott Laboratories
57
Mark PloofMedtronic PLC
N/A
Mark WilterdingEdwards Lifesciences
N/A
Shirley StacyAlign Technology
N/A
Ivan FongMedtronic PLC
62
Christine McCauleyEdwards Lifesciences
58
Michael MahoneyBoston Scientific
58
Darleen CaronSiemens Healthineers AG
59
Elaine LeavenworthAbbott Laboratories
64
Andrea WainerAbbott Laboratories
53
Zelko RelicAlign Technology
58
Jochen SchmitzSiemens Healthineers AG
57
Spencer StilesStryker
46
Jennifer KirkMedtronic PLC
48
Christian KlaussnerSiemens Healthineers AG
N/A
Andre HartungSiemens Healthineers AG
N/A
Todd BrintonEdwards Lifesciences
N/A
John MoriciAlign Technology
56
James YoungAbbott Laboratories
N/A
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts. INSULET CORP operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1169 people. Insulet (GOV) is traded on Frankfurt Exchange in Germany and employs 2,600 people.

Management Performance

Insulet Leadership Team

Elected by the shareholders, the Insulet's board of directors comprises two types of representatives: Insulet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Insulet. The board's role is to monitor Insulet's management team and ensure that shareholders' interests are well served. Insulet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Insulet's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Kapples, Sr Counsel
Wayde McMillan, Ex Treasurer
Angela Wiczek, Sr Communications
Charles Alpuche, Ex COO
Lauren Budden, Chief VP
James Hollingshead, CEO Pres
Michael Spears, VP Compliance
Bret Christensen, Ex Officer
Deborah CPA, VP Relations
Shacey Petrovic, Director Advisor

Insulet Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Insulet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Insulet Stock

When determining whether Insulet is a strong investment it is important to analyze Insulet's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Insulet's future performance. For an informed investment choice regarding Insulet Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Insulet Stock please use our How to Invest in Insulet guide.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Please note, there is a significant difference between Insulet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insulet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insulet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.